Gina Mauro

Articles

FDA Approves Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma

March 29, 2021

The FDA has approved idecabtagene vicleucel as the first BCMA-directed CAR T-cell therapy for patients with relapsed/refractory multiple myeloma after 4 or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody.

Immunotherapy and ADCs Make Headway in Metastatic TNBC

March 22, 2021

Anthracyclines and taxanes remain a backbone in the early-stage setting of triple-negative breast cancer as further evaluations of immunotherapy in the neoadjuvant and adjuvant settings needs to be conducted—efforts that will continue to shape the treatment paradigm.

Pembrolizumab-Ipilimumab Combo Boosts Toxicity, Not Survival in NSCLC

February 07, 2021

Pembrolizumab (Keytruda) combined with ipilimumab (Yervoy) did not improve survival and had higher rates of toxicity compared with pembrolizumab monotherapy as a first-line treatment for patients with metastatic non–small cell lung cancer (NSCLC) who had a PD-L1 tumor proportion score (TPS) of 50% or greater, and did not harbor EGFR or ALK aberrations.

FDA Approves Naxitamab-gqgk for Pediatric and Adult High-Risk Neuroblastoma

November 26, 2020

The FDA has granted an accelerated approval to naxitamab-gqgk (Danyelza) for use in combination with granulocyte-macrophage colony-stimulating factor as a treatment for pediatric patients 1 year of age and older and adult patients with relapsed/refractory high-risk neuroblastoma in the bone or bone marrow who have demonstrated a partial response, minor response, or stable disease to prior treatment.

Tebentafusp Boosts Survival in Metastatic Uveal Melanoma

November 25, 2020

Tebentafusp (IMCgp100) showed superiority in overall survival (OS) compared with investigator’s choice of therapy in patients with previously untreated metastatic uveal melanoma, according to results of a preplanned interim analysis of the phase 3 IMCgp100-202 trial (NCT03070392).

Chemotherapy-Induced Neutropenia: Plinabulin/Pegfilgrastim Combo May Help

November 21, 2020

The combination of plinabulin and pegfilgrastim (Neulasta) showed a statistically significant improvement in the rate of prevention of grade 4 neutropenia versus pegfilgrastim alone in patients with cancer undergoing chemotherapy.